A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer
A Phase II Study of Docetaxel and Carboplatin as Second Line Chemotherapy in First Relapse of Platinum Sensitive Epithelial Ovarian Cancer
Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit
A PHASE2 clinical study on Ovarian Epithelial Cancer Recurrent, this trial is completed. The trial is conducted by Nordic Society of Gynaecological Oncology - Clinical Trials Unit and has accumulated 7 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Dec 2019 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jun 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
For direct contact, visit the study record on ClinicalTrials.gov .